After disastrous Galapagos deal, Gilead finds new rheumatoid arthritis partner
Gilead is looking for another shot at treating rheumatoid arthritis after its massive Galapagos deal fell flat in the face of an FDA rejection and, more recently, a withdrawn Phase I of another asset for the inflammatory disease. The California biopharma, coming off a…#gilead #gs5718 #nanodisc #googles #finish #danieloday #massivegalapagos #irak4 #evoq #disease
Source: Reuters: Health - Category: Consumer Health News Source Type: news